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Abstract. The incidence of hearing loss in patients with rheumatoid arthritis (RA) and the treatment have been 
differently reported. The aims of this study were to establish the presence and to differentiate the type of hearing loss in 
patients with RA, and to investigate the results of corticosteroid and methotrexate treatment on hearing loss in RA. 
Longitudinal, prospective study included 87 patients aged between 18 and 70 years diagnosed with RA. Disease Activity 
Score (DAS 28 Se) and Health Assessment Questionnaire (HAQ) were measured. 38 Patients were treated with 
prednisone; intratympanic appliction was used in 11 persons, and in case of weak or absent improvement after 
steroids methotrexate was applied for further treatment. Predominantly sensorineural hearing loss was present in 
56.3% of the patients, without correlation with the duration of disease and clinical activity of RA. Corticosteroid therapy, 
both peroral or intratympanic contributed to hearing improvement in 60.0%. Audiometric tests are recommended in 
patients who suffer from RA in order to control hearing in rheumatoid arthritis and analyze the effect of proposed 
therapeutic procedures. 




Rheumatoid arthritis (RA) is a disease of unknown origin, 
characterized by disseminated erosions of articulations, and 
different systemic inflammatory changes. Humoral im-
mune alterations (rheumatoid factor, interferon gamma, 
interleukin 2), as well as cellular alterations (lymphocyte 
activation) are characteristic for RA. Reduced complement, 
leukocytosis, increased sedimentation, and higher gam-
maglobuline level are usually found. The diagnosis is 
predominantly based on clinical, radiological, and 
laboratory parameters [1,2]. 
RA causes proliferative synovitis in symmetric pe-
ripheral joints, which differentiates it from other systemic 
diseases of connective tissue. Frequent multiorganic 
changes, such as pericardial effusion, subcutaneous nodes, 
polyneuropathy, vasculitis, nephropathy, and keratocon-
junctivitis are characteristic for RA.  
Hearing and balance impairment has been documented 
in patients with RA. Concerning hearing loss, bilateral, 
symmetric, slowly progressive hypoacousia predominates 
in these patients [3,4]. 
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Previous researches resulted in controversial data on 
the incidence and treatment of hearing loss in RA [57]. 
The aims of this study were: 
1. To document the presence and type of hearing 
loss in patients with RA. 
2. To compare activity and clinical parameters of 
RA with hearing status. 
3. To examine the effectiveness of corticosteroid and 
methotrexate treatment on hearing loss in RA. 
Patients and Methods 
Longitudinal, prospective study comprising of 87 patients 
aged between 18 and 70 years diagnosed with RA was 
conducted during the period 2002-2010 at the Institute for 
Rheumatology and Clinic for Otorhinolaryngology. The 
mean age was 56.2±.8.7 years, female to male ratio was 
70:17, and average duration of disease was 13.4±6.1 years.  
The diagnosis was made according to the American 
College of Rheumatology Classification Criteria [1] 
which included: morning rigidity of joints, arthritis of 
more than 3 joints, arthritis of hands, all of them lasting 
for at least 6 weeks, subcutaneous nodes, seropositivity 
for RF, and radiologic erosions and decalcifications. 
Exclusion criteria were: other causes for conductive and 
sensorineural hearing loss, other systemic and chronic 
diseases, professional noise exposure, malignant diseases, 
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use of ototoxic and immunomodulator drugs. Laboratory 
tests included: sedimentation rate, leukocytes, fibrinogen, 
immunoglobulins, CRP, and RF. 
Disease Activity Score (DAS 28 Se) was measured and 
Health Assessment Questionnaire (HAQ) was  conducted. 
DAS 28 Se is index with strong correlation to the functional 
ability of patients, as well as with the outcome of the 
disease. The results were divided into: 3.2-5.1 moderate 
activity, and >5.1 indicating high activity. HAQ scale 
comprises of 20 questions in 8 categories. The results range 
from 0.0 (the best) to 3.0 (the worst functional ability). 
The patients gave written consent, and the study was 
approved by the Institutional Ethics Committee. 
Control group included 40 healthy subjects with 
similar age (average 55.3±6.2 years), and sex ratio (F: M 
ratio 31:9). 
Hearing threshold for seven frequencies was measured 
using audiometer Madsen ZO 2020. Improvement of 
hearing was defined as the increase for more than 15 dB 
for one frequency (250, 500, 1000, 2000, 4000, 6000, 8000 
Hz), or any improvement for two or more frequencies. 
No previous steroid treatment was given to any patient 
for at least for six months.  
The patients with hearing loss were offered peroral or 
transtympanic steroid therapy. 38 patients were treated 
with prednisone (30 days, peroral dose 60 mg/day). In-
tratympanic appliction was used in 11 persons 
(methylprednisolone, weekkly 0,5 ml in 40 mg/ml). 
Weak or absent improvement after steroids was further 
treated by methotrexate (7,5 mg/wk, with gradual in-
crease to 25 mg/ml, for 8 weeks). 
Student’s t test and chi2 test were used, and statistical 
significance limit was defined as p<0.05. 
Results 
Among patients with RA a total of 49 patients (56.3%) had 
hearing loss. There were 41 females, and 8 male patients, 
without significant difference from the patients with nor-
mal hearing. Hearing loss was predominantly sensorineu-
ral, documented in 91.8% of them, and in other 8.2% it 
was conductive, or mixed. Hearing loss accompanied by 
tinnitus, fullness, or vertigo was verified in 19.5% of pa-
tients, while bilateral progressive sensorineural hearing 
loss was present in 10.3% of them. Subjective average 
duration of hearing loss was 3.5±2.3 years.  
Control group had hearing loss in 12.5 %, and it was 
mainly mild sensorineural. Distribution of patients 
across age was similar in both groups. 
Longer duration of RA, as well as higher values of 
DAS 28 Se, and HAQ scale produced more frequent 
incidence of altered hearing. However, the data did not 
reach statistical significance for any of these parameters 
(Table 1). 
After peroral steroid therapy hearing improvement 
was documented in 60.5 % of the patients, while in others 
hearing remained the same. Intratympanic application of 
steroids resulted in better hearing in 63.6% of the patients 
(Table 2). Improvement of hearing was achieved only 
for higher frequencies, over 2000 Hz. Also, better results 
were achieved for mild to moderate initial hearing loss, 
than for pronounced sensorineural alteration of hearing. 
After follow-up for three to five months there were no 
significant changes of obtained improvement (Table 3). 
In total, 38.8% of the patients did not have any 
change of hearing after steroid therapy. However, only 
47.4% of them accepted further methotrexate therapy. 
The results of such treatment were not satisfactory, with 
improvement in only 11.1 % (Table 2). 
Table 1 Clinical characteristics and hearing loss in patients with rheumatoid arthritis 
Parameter RA without HL RA with HL RA Total 
Sex 
Female 29  (76.3 %) 41  (85.4 %) 70  (80.5 %) 
Male 9  (23.7 %) 8  (14.6 %) 17 (19.5 %) 
Age (y) 
4150 7  (18.4 %) 8  (6.3 %) 15  (17.2 %) 
5160 18  (47.4 %) 21  (42.9 %) 41 (47.1 %) 
6170 10  (26.3 %) 13  (32.6 %) 24  (27.6 %) 




010 23  (60.5 %) 17  (34.7 %) 40  (46.0 %) 
1120 11  (30.0 %) 25  (51.0 %) 36  ( 41.4 %) 
2130 3  (7.9 %) 6  (12.3 %) 9  (10.3 %) 
>30 1  (2.6 %) 1  (2.0 %) 2  (2.3 %) 
DAS 28 Se 
<5.1 7  (18.4 %) 3  (6.1 %) 10  (11.5 %) 
>5.1 31  (81.6 %) 46  (93.9 %) 77  (88.5 %) 
HAQ 
<1.0 2  (5.3 %) 1  (2.0 %) 3  (3.4 %) 
1,1252,0 20  (52.6 %) 22  (44.9 %) 42  (48.3 %) 
>2.125 16  (42.1 %) 26  (53.1 %) 42  (48.3 %) 
RA = rheumatoid arthritis, HL = hearing loss, DAS 28Se = Disease Activity Score, HAQ = Health Assessment Questionnaire  
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Subjective assessment of patients concerning their 
hearing was comparable to audiometric data, but overall 
estimation of treatment improvement was lower than 
found on tonal audiometry (42.9% for subjective versus 
61.2% improvement for audiometry) (Table 2). 
Discussion 
Hearing loss in patients with rheumatoid arthritis (RA) 
is differently reported, usually affecting two thirds of 
them, but the values are ranging from 25.2% to 72.2%. 
Hearing loss in RA was significantly worse for 200, 
500, and 6000 Hz [2,3,8]. There are also reports that 
found no significant hearing loss in RA compared to 
control group with matched age and gender [9].  
Sensorineural hearing loss in RA is attributed to vas-
culitis caused by immune complexes inside inner ear, 
antibodies against inner ear, and ototoxic effects of 
drugs used for treatment of RA [10]. 
Transient evoked otoacoustic emissions in RA were 
found to be lower than in controls. Distortion product of 
otoacoustic emissions in RA patients were similar to con-
trol [9,11]. Acoustic reflexes were with normal thresholds, 
but with occasional prolonged latency. Besides increased 
hearing threshold, patients with RA have higher air-bone 
gaps, and increased wave I latency on ABRs [12,13]. 
Conductive hearing loss was less frequently reported in 
patients with RA, ranging from 4% to 17.1% [1,3]. The 
supposed mechanisms were hypermobility of conductive 
middle ear mechanism, or discontinuity of ossicular chain. 
Tympanometric studies did not find any important changes 
[1,14].  
The incudo-malleolar and incudo-stapedial joints are 
true diarthroses, and may be subjected to the same 
Table 2 Results of different treatment for hearing loss in rheumatoid arthritis judged by audiometry  
and subjective  assessment of  patients 
Treatment No Audiometry Subjective assessment 
 Initial HL  Improved Unchanged Improved Unchanged 
Cortico 
per os 
2030 dB 17  13  (76.5 %) 4  (23.5 %) 10  (58.8 %) 7  (41.2 %) 
3140 dB 16 9  (56.3 %) 7  (43.7 %) 6  (37.5 %) 10  (62.5 %) 
>40 dB 5 1  (20.0 %) 4  (80.0 %) 0  (0.0 %) 5  (100 %) 
All cases 38 23 (60.5%) 14 (36.8%) 16 (42.1 %) 22 (57.9 %) 
Cortico 
intratymp 
2030 dB 1 1  (100 %) 0  (0.0 %) 1  (100 %) 0  (0.0 %) 
3140 dB 5 4  (80.0 %) 1  (20.0 %) 3  (60.0 %) 2  (40.0 %) 
>40 dB 5 2  (40.0 %) 3  (60.0 %) 1  (20.0 %) 4  (80.0 %) 
All cases 11 7 (63.6 %) 4 (36.4 %) 5 (45.5 %) 6 (54.5 %) 
MTX 
2030 dB 2 0  (0.0 %) 2  (100 %) 0  (0.0 %) 2  (100 %) 
3140 dB 4 1  (25.0 %) 3  (75.0 %) 0  (0.0 %) 4  (100 %) 
>40 dB 3 0  (0.0 %) 3  (100 %) 0  (0.0 %) 3  (100 %) 
All cases 9 1 (11.1 %) 8 (88.9 %) 0 (0.0 %) 9 (100 %) 
MTX = methotrexate, HL = hearing loss 
Table 3 Improvement of hearing in dB after different treatment modalities and after follow-up for hearing loss  
in rheumatoid arthritis across frequencies. 
Treatment 125 Hz 250 Hz 500 Hz 1 KHz 2 Hz 4 KHz 6 KHz 8 KHz 
Cortico 
per os 
Before 21.4±3.2 21.4±3.3 21.4±3.2 30.6±5.1 36.5±7.1 42.5±4.7 48.6±7.1 51.3±8.5 
After 19.4±4.2 21.4±5.1 21.4±5.1 26.4±3.2 30.6±5.1 30.6±5.1 40.3±4.4 42.5±4.7 
 dB 2.0 0.0 0.0 4.2 5.9
* 11.9* 8.3* 8.8* 
Follow 19.9±5.1 22.2±4.8 20.7±6.1 28.3±4.1 32.7±6.1 32.5±4.8 43.2±5.6 46.2±5.5 
 dB  1.5 1.0 0.7 1.3 3.2 10.0
* 5.4* 5.1* 
Cortico 
intratymp 
Before 23.8±3.4 23.8±3.4 23.8±3.4 40.6±5.9 40.6±5.9 50.1±6.6 54.2±7.9 55.8±9.9 
After  20.5±4.9 20.5±4.9 23.8±3.4 36.5±7.1 36.5±7.1 38.7±8.2 38.7±8.2 44.6±9.7 
 dB 3.3 3.3 0.0 4.1 4.1 11.4
* 15.5* 11.2* 
Follow 21.7±6.3 24.2±6.1 22.4±5.1 37.2±8.1 39.7±6.2 40.2±9.9 35.7±7.6 46.9±9.3 
 dB 2.1 0.6 0.6 3.4 0.9 9.9
* 18.5* 8.9* 
MTX 
Before 28.8±5.5 25.6±5.9 25.6±5.9 30.3±9.7 39.5±7.2 55.1±8.5 55.1±8.5 54.8±7.2 
After 28.2±3.4 28.8±3.4 25.6±5.1 25.6±5.1 35.6±7.3 45.7±9.8 51.1±8.0 54.8±9.2 
 dB 0.6 3.2 0.0 4.7 4.1 9.4
* 4.0 0.0 
Follow 28.8±5.5 26.3±7.1 25.6±5.9 30.7±8.3 40.2±8.6 45.7±9.9 52.6±9.1 55.3±8.7 
 dB 0.0. 0.7 0.0 0.4 0.7 5.4 2.5 -0.5 
MTX = methotrexate, * = significant 
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rheumatoid lesions. Scanning electron microscopic study 
of auditory ossicles from patients with RA confirmed 
significantly higher incidence of surface and articular 
changes. Longer duration of disease caused more intense 
ossicular alterations [15]. 
Hearing was worse in older patients, with longer du-
ration of disease, with active disease, and RA nodules. 
Decrease of hearing threshold significantly correlated to 
the duration of RA, with all frequencies affected after 15 
years of disease [10]. The results were opposite in other 
studies [16]. For example, no correlation between hearing 
loss and age, sex, disease duration, disease characteristics, 
and therapy were documented [7,9,28].  
There is no clear association between the activity of 
RA and hearing loss [1]. The increase of sedimentation 
rate, interleukin 6, metalloproteinase 3 correlated well, 
contrary to RF [3].  
The recovery of hearing loss in persons with RA was 
not sufficiently studied. A positive result of Western 
Blot predicted functional recovery of hearing in patients 
with RA [3].  
Steroid treatment of autoimmune ear diseases produced 
significantly better results in cases without systemic dis-
eases (excellent results 33% versus 25%) [17,18]. Gluco-
corticoids can reverse hearing loss; however, their im-
portant side effects prevent long term treatment in chronic 
diseases. Experimental studies in C3. MRL-Fas(lpr) au-
toimmune mice treated with corticoids confirmed better 
hearing threshold, and reduced anti-nuclear antibodies and 
immune complexes 19]. 
Methotrexate is considered as a gold standard for 
patients with RA, mainly because of its tolerability, 
efficacy, and ease of use. Methotrexate treatment was 
used for immune mediated cochleovestibular diseases 
(mean duration 12.9 months) and it improved hearing in 
69.6% [20,21]. Other studies concluded that methotrexate 
in low doses (7.5 to 20 mg/wk) improved hearing 
and  balance in autoimmune inner ear disease (AIED). 
However, later randomized, double-blind, placebo con-
trolled trial reported that methotrexate was not effective in 
maintaining the hearing improvement achieved with proni-
sone therapy in patients with AIED [7]. 
Some other therapeutical modalities for hearing loss 
in RA were proposed and tested. TNFalpha inhibitor in 
combination with methotrexate was used in autoimmune 
sensorineural hearing loss [22]. Etanercept is a powerful 
antagonist of TNF that binds to and inactivates the cy-
tokines. However, substantial efficacy of etanercept has 
not been confirmed for improvement of hearing in pa-
tients with immune mediated cochlovestibular disorders 
[23]. Vasodilatators and antioxidants were also proposed 
for treatment of hearing loss in RA [13]. Successful use of 
adalimumab was verified for RA with sensorineural hear-
ing loss [24]. 
The highest levels of steroids in perilymph were 
found after intratympanic injection. Also, limited per-
meability of the blood-labyrinth barrier prevents sys-
temic absorption of applied corticosteroids [25,26]. 
There were no significant differences concerning age 
and sex in RA patients with and without hearing loss. Also, 
age-matched control group eliminated the effect of possible 
associated presbyacousis. More importantly, duration of 
disease, DAS and HAQ scales indicated higher incidence 
of hearing affection, but the differences were not signifi-
cant. So, we need more specific tests to predict inner ear 
changes in patients with RA [2730]. 
According to the results of this study steroids resulted 
in hearing improvement in approximately 60.0%, both for 
peroral and intratympanic application. Contrary to this, 
methotrexate had virtually no influence of hearing. The 
disadvantage of steroid treatment is limited time of use. 
Also, the prediction of success or failure of treatment is 
difficult. Thus, initial peroral steroid therapy is advisa-
ble in RA with hearing loss. This is also acceptable for 
the patients. The positive outcome of such option can be 
further treated with steroids intrtympanically. Though 
intratympanic use of steroids was reported in references, 
there are no references for application for hearing loss 
in RA [25,26]. 
The slight discordance found in this study between 
patient’s assessment and audiometric findings after the 
therapy is very important, since the patients must use 
medication and tolerate its side effects. They usually 
report less favorable results of treatment than indicated 
by audiometric tests. 
New studies should be undertaken to compare dif-
ferent options of treatment of hearing loss in RA. 
Conclusion 
Hearing loss was present in 56.3% of the patients 
with rheumatoid arthritis, and it was predominantly senso-
rineural. Duration of disease and clinical activity of 
rheumatoid arthritis did not correlate to the incidence of 
hearing loss. Corticosteroid therapy, either peroral or 
intratympanic resulted in hearing improvement in about 
60.0% of these patients. Results of methotrexate treat-
ment of hearing loss in rheumatoid arthritis were unsatis-
factory. Intratympanic steroids are safe for prolonged 
treatment of hearing loss in RA.  Audiometric tests are 
recommended in order to control hearing in rheumatoid 
arthritis, and analyze the effect of proposed therapeutic 
procedures. 
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